Sanofi

News

AZ, Sanofi get first green light for RSV prophylactic antibo...

AstraZeneca and Sanofi have secured approval in the EU for Beyfortus, the first single-dose drug to protect newborns and infants from respiratory syncytial virus (RSV) infections.<

News

Radiology technician examens mammography test on location

After setbacks for Roche and Sanofi, AZ scores oral SERD win

AstraZeneca seems to have dodged the problems besetting other developers of oral selective oestrogen receptor degrader (SERD) drugs with a phase 2 win for its candidate camizestrant in a ph

News

Weak data for Fasenra undermine AZ's ambitions for the drug

AstraZeneca's IL-5 inhibitor Fasenra is already making blockbuster sales from its use in eosinophilic asthma, but the drugmaker's efforts to expand its label keep running into difficulties.

Events

Reuters Pharma 2022 - a day one overview - part 1

The Reuters Pharma event 2022 began as a bustling industry affair yesterday, based out of the Nice Acropolis convention centre on France’s balmy south coast.

News

Sanofi wagers $400m on miRecule muscular dystrophy therapy

Sanofi has added to its rare disease pipeline by licensing an antibody-RNA conjugate (ARC) for facioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disorder, from US biotech miRe

News

FDA clears Dupixent as first drug for rare skin disorder

Sanofi and Regeneron have claimed the first approval in the US for a drug for prurigo nodularis, after the FDA gave a green light to Dupixent as a treatment for adults with the rare skin di

AZ, Sanofi get first green light for RSV prophylactic antibo...

After setbacks for Roche and Sanofi, AZ scores oral SERD win

Weak data for Fasenra undermine AZ's ambitions for the drug

Reuters Pharma 2022 - a day one overview - part 1

Sanofi wagers $400m on miRecule muscular dystrophy therapy

FDA clears Dupixent as first drug for rare skin disorder

Ambrosia's sweet $100m round, and other biofinancings

Using AI-driven synthetic personas to take your insights fur...

Sanofi

Editor's Picks